paclitaxel + non-pegylated liposomal doxorubicin + carboplatin

This is a multi-agent chemotherapy regimen combining three small-molecule cytotoxic agents: paclitaxel (a microtubule-stabilizing taxane), non-pegylated liposomal doxorubicin (a liposomal anthracycline formulation without PEG coating, delivering doxorubicin that intercalates DNA and inhibits topoisomerase II), and carboplatin (a platinum alkylating-like agent that forms DNA crosslinks). It is conceptually related to triplet regimens that add a doxorubicin formulation to the standard paclitaxel-carboplatin backbone used in ovarian and other gynecologic malignancies; phase I work established feasible dosing of a doxorubicin liposomal formulation with carboplatin and paclitaxel, while multiple randomized trials have compared pegylated liposomal doxorubicin plus carboplatin against paclitaxel plus carboplatin in ovarian cancer settings. However, widely studied combinations typically used pegylated liposomal doxorubicin rather than a non-pegylated liposomal product. The regimen’s rationale is non-overlapping mechanisms: mitotic arrest from paclitaxel, DNA intercalation/topoisomerase II inhibition from doxorubicin, and platinum-induced DNA damage from carboplatin.[4][3][5]

Other names

paclitaxel + liposomal doxorubicin + carboplatin